Literature DB >> 19761839

Replication of rubella vaccine population genetic studies: validation of HLA genotype and humoral response associations.

Inna G Ovsyannikova1, Robert M Jacobson, Robert A Vierkant, Megan M O'Byrne, Gregory A Poland.   

Abstract

Purported genetic associations found in population studies require validation for confirmation. We previously reported rubella vaccine-induced immune responses and HLA associations in 346 adolescents, age 12-18 years (1st cohort), following two doses of a rubella-containing vaccine. We sought to replicate the associations discovered in that work by verifying these associations in a new cohort of 396 subjects, age 11-19 years (2nd cohort), all having had two doses of a rubella-containing vaccine. We found that B*2705 (median 1st cohort 20.9 IU/ml, p=0.028; 2nd cohort 20.5 IU/ml, p=0.001) and DPA1*0201 (median 1st cohort 32.5 IU/ml, p=0.048; 2nd cohort 25.8 IU/ml, p=0.025) alleles were consistently associated with lower rubella-induced antibodies. Further, DPB1*0401 (median 1st cohort 43.5 IU/ml, p=0.021; 2nd cohort 36.2 IU/ml, p=0.002) alleles were associated with higher antibody levels in both populations. The association of DRB1*04-DQB1*03-DPB1*03 (mean 1st cohort 25.2 IU/ml, p=0.011; 2nd cohort 21.4 IU/ml, p=0.032) and DRB1*15/16-DQB1*06-DPB1*03 (1st cohort 16.3 IU/ml, p=0.043; 2nd cohort 19.1 IU/ml, p=0.023) haplotypes with lower rubella-specific antibodies was observed in both studies. This study provides confirmatory evidence for an association between specific class I and II HLA markers and haplotypes with rubella vaccine-induced humoral responses and lends further weight to their influence on rubella immune responses.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19761839      PMCID: PMC2783524          DOI: 10.1016/j.vaccine.2009.08.109

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  15 in total

1.  Twin studies of immunogenicity--determining the genetic contribution to vaccine failure.

Authors:  P L Tan; R M Jacobson; G A Poland; S J Jacobsen; V S Pankratz
Journal:  Vaccine       Date:  2001-03-21       Impact factor: 3.641

2.  Score tests for association between traits and haplotypes when linkage phase is ambiguous.

Authors:  Daniel J Schaid; Charles M Rowland; David E Tines; Robert M Jacobson; Gregory A Poland
Journal:  Am J Hum Genet       Date:  2001-12-27       Impact factor: 11.025

Review 3.  Genome-wide association studies for common diseases and complex traits.

Authors:  Joel N Hirschhorn; Mark J Daly
Journal:  Nat Rev Genet       Date:  2005-02       Impact factor: 53.242

4.  Consistent associations of HLA class I and II and transporter gene products with progression of human immunodeficiency virus type 1 infection in homosexual men.

Authors:  I P Keet; J Tang; M R Klein; S LeBlanc; C Enger; C Rivers; R J Apple; D Mann; J J Goedert; F Miedema; R A Kaslow
Journal:  J Infect Dis       Date:  1999-08       Impact factor: 5.226

5.  Human leukocyte antigen class II alleles and rubella-specific humoral and cell-mediated immunity following measles-mumps-rubella-II vaccination.

Authors:  Inna G Ovsyannikova; Robert M Jacobson; Robert A Vierkant; Steven J Jacobsen; V Shane Pankratz; Gregory A Poland
Journal:  J Infect Dis       Date:  2005-01-14       Impact factor: 5.226

6.  Human leukocyte antigen haplotypes in the genetic control of immune response to measles-mumps-rubella vaccine.

Authors:  Inna G Ovsyannikova; V Shane Pankratz; Robert A Vierkant; Robert M Jacobson; Gregory A Poland
Journal:  J Infect Dis       Date:  2006-01-27       Impact factor: 5.226

7.  The contribution of HLA class I antigens in immune status following two doses of rubella vaccination.

Authors:  Inna G Ovsyannikova; Robert M Jacobson; Robert A Vierkant; Steven J Jacobsen; V Shane Pankratz; Gregory A Poland
Journal:  Hum Immunol       Date:  2004-12       Impact factor: 2.850

Review 8.  Aspects of genetic susceptibility to human infectious diseases.

Authors:  Adrian V S Hill
Journal:  Annu Rev Genet       Date:  2006       Impact factor: 16.830

Review 9.  Application of pharmacogenomics to vaccines.

Authors:  Gregory A Poland; Inna G Ovsyannikova; Robert M Jacobson
Journal:  Pharmacogenomics       Date:  2009-05       Impact factor: 2.533

Review 10.  Genetic susceptibility to infectious diseases: big is beautiful, but will bigger be even better?

Authors:  David Burgner; Sarra E Jamieson; Jenefer M Blackwell
Journal:  Lancet Infect Dis       Date:  2006-10       Impact factor: 25.071

View more
  30 in total

1.  Consistency of HLA associations between two independent measles vaccine cohorts: a replication study.

Authors:  Inna G Ovsyannikova; V Shane Pankratz; Robert A Vierkant; Robert M Jacobson; Gregory A Poland
Journal:  Vaccine       Date:  2012-01-25       Impact factor: 3.641

Review 2.  Adversomics: a new paradigm for vaccine safety and design.

Authors:  Jennifer A Whitaker; Inna G Ovsyannikova; Gregory A Poland
Journal:  Expert Rev Vaccines       Date:  2015-05-02       Impact factor: 5.217

Review 3.  Vaccinomics: current findings, challenges and novel approaches for vaccine development.

Authors:  Inna G Ovsyannikova; Gregory A Poland
Journal:  AAPS J       Date:  2011-06-14       Impact factor: 4.009

Review 4.  Vaccinomics and a new paradigm for the development of preventive vaccines against viral infections.

Authors:  Gregory A Poland; Inna G Ovsyannikova; Richard B Kennedy; Iana H Haralambieva; Robert M Jacobson
Journal:  OMICS       Date:  2011-07-06

Review 5.  Searching for the human genetic factors standing in the way of universally effective vaccines.

Authors:  Alexander J Mentzer; Daniel O'Connor; Andrew J Pollard; Adrian V S Hill
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  2015-06-19       Impact factor: 6.237

6.  Analysis of HLA A*02 association with vaccine efficacy in the RV144 HIV-1 vaccine trial.

Authors:  Andrew J Gartland; Sue Li; John McNevin; Georgia D Tomaras; Raphael Gottardo; Holly Janes; Youyi Fong; Daryl Morris; Daniel E Geraghty; Gustavo H Kijak; Paul T Edlefsen; Nicole Frahm; Brendan B Larsen; Sodsai Tovanabutra; Eric Sanders-Buell; Allan C deCamp; Craig A Magaret; Hasan Ahmed; Jodie P Goodridge; Lennie Chen; Philip Konopa; Snehal Nariya; Julia N Stoddard; Kim Wong; Hong Zhao; Wenjie Deng; Brandon S Maust; Meera Bose; Shana Howell; Adam Bates; Michelle Lazzaro; Annemarie O'Sullivan; Esther Lei; Andrea Bradfield; Grace Ibitamuno; Vatcharain Assawadarachai; Robert J O'Connell; Mark S deSouza; Sorachai Nitayaphan; Supachai Rerks-Ngarm; Merlin L Robb; John Sidney; Alessandro Sette; Susan Zolla-Pazner; David Montefiori; M Juliana McElrath; James I Mullins; Jerome H Kim; Peter B Gilbert; Tomer Hertz
Journal:  J Virol       Date:  2014-05-14       Impact factor: 5.103

7.  HLA alleles associated with the adaptive immune response to smallpox vaccine: a replication study.

Authors:  Inna G Ovsyannikova; V Shane Pankratz; Hannah M Salk; Richard B Kennedy; Gregory A Poland
Journal:  Hum Genet       Date:  2014-06-01       Impact factor: 4.132

8.  Genome-wide SNP associations with rubella-specific cytokine responses in measles-mumps-rubella vaccine recipients.

Authors:  Richard B Kennedy; Inna G Ovsyannikova; Iana H Haralambieva; Nathaniel D Lambert; V Shane Pankratz; Gregory A Poland
Journal:  Immunogenetics       Date:  2014-05-09       Impact factor: 2.846

9.  A study of vaccine-induced immune pressure on breakthrough infections in the Phambili phase 2b HIV-1 vaccine efficacy trial.

Authors:  T Hertz; M G Logan; M Rolland; C A Magaret; C Rademeyer; A Fiore-Gartland; P T Edlefsen; A DeCamp; H Ahmed; N Ngandu; B B Larsen; N Frahm; J Marais; R Thebus; D Geraghty; J Hural; L Corey; J Kublin; G Gray; M J McElrath; J I Mullins; P B Gilbert; C Williamson
Journal:  Vaccine       Date:  2016-10-15       Impact factor: 3.641

10.  Genetic polymorphisms associated with rubella virus-specific cellular immunity following MMR vaccination.

Authors:  Richard B Kennedy; Inna G Ovsyannikova; Iana H Haralambieva; Nathaniel D Lambert; V Shane Pankratz; Gregory A Poland
Journal:  Hum Genet       Date:  2014-08-07       Impact factor: 4.132

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.